Michael S. Perry, a Director at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 11,600 shares of common stock on Aug. 18, <a href="https://bitcomme.com/reviewing-the-trends-in-ransomware-attacks-in-2026/” title=”Reviewing the trends in ransomware attacks in 2026″>2026, according to an SEC Form 4 filing.
Transaction summary
Transaction value based on SEC Form 4 weighted average sale price ($87.30); post-transaction value based on Aug. 18, 2026, market close ($87.90).
Key questions
-
What were the specific execution details of this open-market sale?
The shares were disposed of in multiple transactions at prices ranging from $87.20 to $87.44, with the reporting person providing full trade data to the company and the SEC upon request. -
How does this transaction impact the insider’s total stake in the company?
By selling 11,600 shares, the director liquidated 9% of his direct holdings. However, he remains a stakeholder with 0.0791% of the company’s equity and continues to hold common stock underlying unvested restricted stock units. -
What is the current market valuation context for Arrowhead Pharmaceuticals?
The Pasadena-based biotechnology company maintains a market capitalization of $12.2 billion, with shares priced at $89.41 as of the Aug. 19, 2026, market close. -
What are the fundamental financial metrics for the firm?
Arrowhead Pharmaceuticals reported trailing twelve-month revenue of $669.5 million and a net loss of $320 million as it continues to advance a therapeutic pipeline centered on RNA interference technology.
Company Overview
Company Snapshot
-
Arrowhead Pharmaceuticals develops innovative biopharmaceutical treatments leveraging RNA interference (RNAi) technology, with a clinical pipeline focused on complex, challenging-to-treat diseases, and generates revenue through therapeutic development and commercialization.
-
The company operates as a discovery-stage to clinical-stage biopharmaceutical enterprise, advancing multiple therapeutic candidates through clinical trials to achieve regulatory approval and subsequent commercialization in the United States market.
-
Arrowhead targets patients with rare genetic diseases and complex liver conditions, including alpha-1 antitrypsin deficiency, positioning itself in the specialty pharmaceutical and orphan drug markets where unmet medical needs remain substantial.
Arrowhead Pharmaceuticals, founded in 1989 and headquartered in Pasadena, California, represents a clinical-stage biopharmaceutical company with a market capitalization of $12.2 billion and 711 employees. The company’s strategic focus on RNAi-based therapeutics provides a differentiated technological platform for addressing genetic and metabolic disorders with limited treatment options. With TTM revenue of $669.5 million and continued investment in its pipeline, Arrowhead demonstrates the capital-intensive nature of biopharmaceutical development. However, the company remains positioned to capture significant value upon successful advancement and commercialization of its clinical candidates.
